Get the latest market trends in your inbox

Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Denver news in your inbox

Catch up on the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Des Moines news in your inbox

Catch up on the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Minneapolis-St. Paul news in your inbox

Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tampa-St. Petersburg news in your inbox

Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Billions of prescriptions are filled electronically every year. Photo: George Frey/Getty Images

A small pharmacy in New York has filed a class-action lawsuit against Surescripts, alleging that the company conspired with other health technology vendors to keep monopoly control over the market for electronically filled prescriptions.

The big picture: Antitrust litigation is piling up quickly against Surescripts, as the company's customers and federal regulators alike believe it has locked competitors out of a space that has become necessary to fill four out of five drug prescriptions.

Between the lines: A lot of the lawsuit, filed by Falconer Pharmacy, builds on allegations from the Federal Trade Commission and Amazon.

  • Namely, it says Surescripts has forced pharmacies and vendors to use only its electronic prescribing network at noncompetitive rates, or else face even higher prices as "non-loyal" customers.
  • Falconer Pharmacy said in the complaint that it pays "at least 17 cents per routing transaction," but Surescripts has previously revealed that more competitive prices would be between one and three cents per transaction.

But, but, but: The lawsuit goes one step further, naming technology vendors RelayHealth (part of McKesson) and Allscripts as co-conspirators.

  • RelayHealth and Allscripts signed contracts that forced them to use Surescripts exclusively, but Surescripts passed along incentive payments to them in return, according to the complaint.
  • McKesson and Allscripts did not immediately respond for comment.

Surescripts CEO Tom Skelton said the company is "disappointed in the allegations."

  • "We take seriously our role in helping serve patients and the people who care for them, and we remain confident that our business practices support that goal.”

The bottom line: Surescripts is one of the most obvious monopolies in health care. The increasing legal heat raises questions about whether regulators and policymakers would advocate for breaking up the company or mandating price concessions.

Editor's note: This post has been updated to note RelayHealth's pharmacy business remains part of McKesson, not Change Healthcare.

Go deeper

26 mins ago - Technology

Exclusive: Facebook's blackout didn't dent political ad reach

Photo: Valera Golovniov/SOPA Images/LightRocket via Getty Images

Americans saw more political ads on Facebook in the week before the 2020 election than they did the prior week despite the company's blackout on new political ads during that period, according to Global Witness, a human rights group that espouses tech regulation.

Why it matters: The presidential election was a key stress test for Facebook and other leading online platforms looking to prove that they can curb misinformation. Critics contend measures like the ad blackout barely made a dent.

Wall Street wonders how bad it has to get

Illustration: Aïda Amer/Axios

Wall Street is working out how bad the economy will have to get for Congress to feel motivated to move on economic support.

Why it matters: A pre-Thanksgiving data dump showed more evidence of a floundering economic recovery. But the slow drip of crumbling economic data may not be enough to push Washington past a gridlock to halt the economic backslide.

2 hours ago - Health

Moderna to file for FDA emergency use authorization for COVID-19 vaccine

Photo illustration by STR/NurPhoto via Getty Images

Moderna announced that it plans to file with the FDA Monday for an emergency use authorization for its coronavirus vaccine, which the company said has an efficacy rate of 94.1%.

Why it matters: Moderna will become the second company to file for a vaccine EUA after Pfizer did the same earlier this month, potentially paving the way for the U.S. to have two COVID-19 vaccines in distribution by the end of the year. The company said its vaccine has a 100% efficacy rate against severe COVID cases.

Get Axios AM in your inbox

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!